BRIDGING
LONGEVITY,
BIOTECH & AI
/REVERSING
AGING
Investing in frontier biotechnologies
that target the root causes
of age-related diseases
BOLD Longevity Growth is a leading global longevity fund investing in frontier biotechnologies to treat the root causes of disease and extend the healthy human lifespan.
The fund specializes in the growth and scaling stages at the intersection of longevity, biotech, and artificial intelligence with a mission to make those technologies affordable and accessible for everyone
We have built a unique set of expertise to help our portfolio companies unlock their impact in longevity.
With our unique expertise, capital, experienced partners, and network of advisors, we help biotech businesses succeed and extend their impact into aging and age-related diseases.
We are supporting the best companies that want to drive the future of health and longevity.
We invest in companies changing the paradigm of how medicine is practiced, and how diseases are diagnosed and treated to enable healthy human life extension.
BOLD Longevity Growth invests in platform technologies making over 5-10x improvements in efficiency and safety, reshaping medical practice and making those technologies more affordable and accessible. We target growth-stage companies focused on root causes of aging and diseases, co-investing with the largest biotech VC funds and big pharma.
Our team’s prior investment track record includes next-generation gene editing that is potentially 10x more efficient than CRISPR; AI-powered ultrasound device that is 20-30x more affordable; and AI cancer detection that aims to increase survival rates by 6-7x.
Our teams prior investment highlights
AI-Driven Drug Discovery for Neurodegenerative Diseases
Biometric Health Tracking Wearables
AI Predictive Surgical Intelligence
Gene Editing / Reproductive
De-Extinction
Generative AI
Drug Discovery & Prediction
Continuous Multi-Analyte Biosensing Platform
We have deep
expertise in aging biology and longevity investments.
Our team brings diverse knowledge from large pharmaceutical companies, biotech entrepreneurship, and biotech venture capital funds. We are supported by a scientific and venture advisory board from world-renowned scientific institutions and venture creation firms, who have collectively co-founded more than 50+ biotech and longevity companies.